HomeGRAL • NASDAQ
add
Grail Inc
Previous close
$38.65
Day range
$36.87 - $38.47
Year range
$12.33 - $63.99
Market cap
1.37B USD
Avg Volume
794.20K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 35.54M | 11.18% |
Operating expense | 146.55M | -37.88% |
Net income | -113.98M | 92.81% |
Net profit margin | -320.69 | 93.53% |
Earnings per share | -3.18 | — |
EBITDA | -91.68M | 49.34% |
Effective tax rate | 25.43% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 602.75M | -37.14% |
Total assets | 2.70B | -17.34% |
Total liabilities | 387.91M | -32.48% |
Total equity | 2.31B | — |
Shares outstanding | 36.05M | — |
Price to book | 0.60 | — |
Return on assets | -11.79% | — |
Return on capital | -13.48% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -113.98M | 92.81% |
Cash from operations | -76.96M | 55.20% |
Cash from investing | 70.37M | 5,177.13% |
Cash from financing | — | — |
Net change in cash | -6.47M | -100.85% |
Free cash flow | -29.88M | 75.95% |
About
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms.
Grail was spun-out from Illumina on June 24, 2024.
Their liquid biopsy was launched in June 2021 and is called the Galleri test. Wikipedia
Founded
2015
Headquarters
Website
Employees
1,000
